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tions,” citing the rarity of home HD in the United States that is accumulated after the time of entry into the study
[3]. Causal mechanisms flow forward in time from theand Japan. It should be pointed out that out-center HD is
still common in Australia and New Zealand, and excellent perspective of the patient. Future information, which has
not been observed at the time of entry into a study, shoulddata are available through the Australia and New Zealand
Transplant (ANZDATA) Registry [2]. Currently, 43% of not be used to predict risk of future events. An added
complexity in examining the blood pressure–allograft sur-HD patients in New Zealand dialyze at home and 3% in
satellite units, while in Australia the figures are 18% and vival relationship is that elevated BP may not only cause,
but may result from decreased allograft function. Ad-41%, respectively [2]. Our dialysis unit, which was estab-
lished in 1969 and serves a population of 480,000, offers justing for renal function at the time the BP reading is
obtained is appropriate to examine the relationship, inde-only home dialysis. We recently published our 30-year
experience [3] reporting a median survival of 7.75 years pendent of renal function, of BP and allograft failure at
or after that point in time. BP measurements taken at thefor home HD patients who were less selected because no
in-center HD program existed. This patient survival was time when the allograft is failing will tend to be higher
because of worsened renal function. Constructing a “base-superior to hospital HD elsewhere in this region. The
quality of life, survival and cost benefits of home HD that line” covariate derived from later BP readings taken when
the allograft is failing will bias the conclusion about thewere recognized in the 1960s still apply today, a fact not
forgotten here. Geographical isolation, with many patients BP-allograft survival relationship. In regression analyses,
the use of events that occur after the time of entry intoliving in isolated rural areas, and an absence of financial
disincentives to prescribing home HD are other reasons a study to predict future events can lead to illogical results
such as their finding that there was an increased risk offor its continued use. Our experience, which is similar to
that of Arkouche et al, suggests that this very successful allograft failure with increasing average time of follow-
up. Allografts that have better survival have longer follow-technique should be utilized more in other parts of the
world. up times.
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Lowering C-peptide levels and
renoprotective therapy
Blood pressure and prediction To the Editor: In a recent editorial by Hebert on reno-
protective therapy, one of the proposed strategies con-of patient outcome
sisted of lowering C-peptide levels, based on animal evi-
dence and human epidemiological data that elevatedTo the Editor: We were initially encouraged by the
recent publication of Cosio et al [1] that supported our insulin levels promote glomerulosclerosis [1]. Exercise,
weight reduction, and diet low in refined sugars were firststudy that demonstrated an increased rate of allograft
failure with increasing levels of blood pressure (BP) [2]. mentioned to lower C-peptide levels “when these patients
develop renal disease” [1]. However, if that proves unsuc-Upon further review, we have concerns about the use of
BP data during follow-up as if they were baseline charac- cessful, a pharmacological approach, which provides some
concerns, was suggested.teristics. In survival analysis, it is improper to use as a
baseline predictor, covariates constructed on information Dimethylbiguanide (metformin) is proposed as an ap-
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propriate therapy to lower insulin levels without promot- be recommended as part of a renoprotective therapy in
our patients with renal disease.ing hypoglycemia. Metformin reduces hyperinsulinemia
by countering insulin resistance. However, metformin may
Yves Clouaˆtrenot be recommended as a renoprotective strategy for most
of our patients. Correspondence to Yves Clouaˆtre, M.D., FRCP(C), Service de ne´phro-
logie, Centre Hospitalier Re´gional de Rimouski, 150 Rouleau, Rimouski,“When choosing metformin, it is essential to ensure
Que´bec, Canada G5L 5T1.normal renal function” [2]. Metformin is contraindicated E-mail: yves.clouatre@ssss.gouv.qc.ca
with a serum creatinine of 1.4 mg/dL or higher for women
and 1.5 mg/dL or higher in men, or an abnormal creatinine REFERENCES
clearance of less than 90 mL/min [2, 3]. Although lactic
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in type 2 diabetes mellitus. Drug Safety 20:489–503, 1999occurring in patients with contraindications to this drug. 3. Jurovich MR, Wooldridge JD, Force RW: Metformin-associated
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